Skip to main content
. 2019 Mar 21;24(5):177–184. doi: 10.1136/bmjebm-2018-111145

Table 1.

Number of EFPIA and PhRMA member and non-member companies in the top 50 biopharmaceutical companies as ranked by 2015 worldwide prescription sales and their public commitment to disclosing clinical trial data

Top 50 companies: membership of EFPIA and/or PhRMA General data sharing statement, n (%) EFPIA/PhRMA principles Five EFPIA/PhRMA joint principles of responsible clinical data sharing
Commitment to sharing clinical trial data with researchers Public availability of CSR synopsis as a minimum Availability of results for trial participants Public certification of adoption of EFPIA/PhRMA commitments Commitment to publish clinical trial data
(phase III minimum)
All five principles
Member (n=30) 26 (86.7) 20 (66.7) 25 (83.3) 22 (73.3) 18 (60.0) 21 (70.0) 24 (80.0) 16 (53.3)
Non-member  (n=20) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total  (n=50) 26 (52.0) 20 (40.0) 25 (50.0) 23 (46.0) 18 (36.0) 21 (42.0) 24 (48.0) 16 (32.0)

CSR, clinical study report; EFPIA, European Federation of Pharmaceutical Industries and Associations; PhRMA, Pharmaceutical Research and Manufacturers of America.